Survey of Changes in Antiplatelet Therapy Based on Japanese Insurance Claims Database

Not Applicable

• Conditions: ischemic cerebrovascular disorder (ICD) patients and ischemic heart disease (IHD) patients

• Registration Number: JPRN-UMIN000052198
• Lead Sponsor: Daiichi Sankyo Co., Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-15
• Study Completion: 2024-01-31
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

(ICD cohort) 1.Patients with antiplatelet prescriptions during baseline period (between 5 months prior to the index date and the index date). 2.Patients with anticoagulant prescriptions between the start of baseline period and the end of the observation period. 3.Patients with indication for anticoagulation therapy (medical history of atrial fibrillation, persistent or paroxysmal atrial fibrillation, and prosthetic heart valve placement). (IHD cohort) 1.Patients with antiplatelet prescriptions between the start of baseline period and 2 weeks prior to the index date. 2.Patients with anticoagulant prescriptions between the start of baseline period and the end of the observation period. 3.Patients with indication for anticoagulation therapy (medical history of atrial fibrillation, persistent or paroxysmal atrial fibrillation, and prosthetic heart valve placement).

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified